In a prospective, double-blinded, double-dummy, randomized study, 69 patients with a hypertensive urgency (systolic blood pressure (SBP) 4220 mm Hg and/or diastolic blood pressure (DBP) 4110 mm Hg) received either captopril or urapidil to reduce of SBP o180 mm Hg and DBP o90 mm Hg and blood pressure was measured by an ambulatory blood pressure unit for at least 12 h. The area-under-thecurve (AUC) of SBP and DBP was 163 (20)/85 (12) mm Hg for the urapidil group and 159 (17)/88 (9) mm Hg for the captopril group (P-values 0.38/ 0.40) and the AUC above 180/90 mm Hg was 4.6 (4.9)/4.7 (5.7) mm Hg versus 2.7 (5.1)/5.3 (6.3) mm Hg (P ¼ 0.12/P ¼ 0.42) demonstrating that intravenous urapidil may be also an useful drug in the treatment of hypertensive urgencies.
Hypertensive urgencies are commonly observed in emergency departments and walk-in-clinics. 1 The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure as well as the International Society of Hypertension (ISH) recommended the use of oral agents for the treatment of hypertensive urgencies, as blood pressure reduction should occur from 6 to 24 h. 2, 3 In the setting of an emergency department, a close followup of these patients is usually impossible. Therefore, many emergency departments have standard procedures that prohibit release of patients with blood pressure in excess of 180/110 mm Hg and treat patients with hypertensive urgencies using intravenous (i.v.) drugs like urapidil or labetalol. 4, 5 These drugs reduce blood pressure sufficiently within a short time and with a low frequency of side effects. 6 However, these procedures are controversially discussed and data demonstrating safety and efficacy of this treatment are lacking. We, therefore, aimed a study to evaluate the safety and efficacy of an i.v. antihypertensive drug compared to the standard oral treatment of patients with hypertensive urgencies.
The study was conducted in the Emergency Department of the General Hospital in Vienna between March 2004 and October 2004 and was approved by the Ethical Committee of the University of Vienna. All patients gave their written informed consent before inclusion of the study. The design of the study was prospective, double-blinded and both drugs (urapidil and captopril) were given in a double-dummy design, that is, the patient received simultaneously an i.v. agent (either urapidil or sodium chloride 0.9%) and an oral agent (captopril or placebo) according to the randomization protocol. The primary inclusion criteria was a hypertensive urgency defined as a systolic blood pressure (SBP) 4220 mm Hg and/or a diastolic blood pressure (DBP) 4110 mm Hg without evidence of end-organ damage on admission to the emergency department. After a resting period of 30 min, blood pressure was recorded again. If blood pressure was still above 220 mm Hg systolic and/or 110 mm Hg diastolic, patients were finally included to the study. Before the application of the study medication, the patient received an ambulatory blood pressure measurement device to record blood pressure every 15 min for next 12 h. Study medication was given in a double-dummy preparation. The patients were randomized either to urapidil (12.5 mg urapidil i.v. and placebo oral) or to captopril (25 mg captopril oral and 10 ml placebo ( ¼ 0.9% sodium chloride) i.v.). Aim of treatment was to reduce SBP below 180 mm Hg and DBP below 90 mm Hg within the first hour after study medication was given. Patients with a sufficient blood pressure reduction were discharged and instructed to re-admit the emergency department at least 12 h later. If blood pressure was still above 180/90 mm Hg after 1 h, application of the study medication was repeated (urapidil group: 12.5 mg urapidil i.v./placebo oral; captopril group: 12.5 mg captopril oral/placebo i.v.) and patients were discharged 2 h after start of treatment. The endpoints were the course of SBP and DBP expressed as area-under-the-curve (AUC) within the first 12 h after drug treatment, the AUC for SBP and DBP above 180/90 mm Hg, and the number of side-effects.
Finally, 56 patients (28 females; 56 (13) years) were included to the study protocol ( Table 1 ). The average observation period was 11.1 (1.9) h.
The AUC of SBP and DBP was 163 (20)/85 (12) mm Hg for the urapidil group and 159 (17)/88 (9) mm Hg for the captopril group, respectively (P-values 0.38/0.40). The course of SBP and DBP did not differ significantly between both groups through the entire observation period (Figure 1 ). Blood pressure decreased significantly within the first hour (urapidil: À46/26 mm Hg; captopril: À38/ 18 mm Hg) in both groups. An increase of blood pressure was observed from the 9th hour after the start of observation in both groups. The AUC above the defined SBP and DBP of 180/90 mm Hg was 4.6 (4.9)/4.7 (5.7) mm Hg in the urapidil group and 2.7 (5.1)/5.3 (6.3) mm Hg in the captopril group (P ¼ 0.12/P ¼ 0.42). Overall, nine adverse effects (urapidil: n ¼ 5; captopril: n ¼ 4) were observed during the study period. The follow-up of the patients after the hypertensive urgency revealed that 42 patients (urapidil: n ¼ 19; captopril: n ¼ 23) had elevated blood pressure values either evaluated by home blood pressure measurement or 24-h ambulatory blood pressure measurement. No evidence of secondary hypertension was observed in the study group.
Our data demonstrate that both drugs are safe and effective in the treatment of patients with hypertensive urgencies. The hemodynamic data as well as the safety data clearly illustrate that the safety and efficacy of an i.v. drug like urapidil is comparable to oral treatment in these patients. We are aware that the use of i.v. drugs in patients with hypertensive urgencies may be criticized, as current guidelines recommend the use of oral agents in these patients. It has been hypothesized that rapid and uncontrolled blood pressure reduction may be harmful in patients with hypertensive urgencies. However, the recommendations against the use of i.v. drugs are based on few reports, including a very small number of patients, which have demonstrated severe adverse events after the use of drugs like sodium nitroprusside, diazoxide or clonidine.
7-10 These drugs are no longer first-line drugs in the treatment of hypertensive crisis and have been replaced by newer drugs like urapidil or labetalol. Safety data of these newer drugs used in the treatment of hypertensive urgencies have been evaluated in different settings. 11 However, no prospective comparative studies neither with a short-term nor long-term follow-up using a head-to-head design (i.v. drug versus oral drug) are available: the lack of scientific evidence concerning the benefit or harm of i.v. drugs in the treatment of hypertensive urgencies was the primary reason for the current study.
For the first time, our study demonstrated a similar safety and efficacy of an i.v. drug in the treatment of hypertensive urgencies compared to an established oral treatment. Additionally, the use of i.v. urapidil did not cause rapid and uncontrolled blood pressure reduction. We are aware that additional comparative studies in patients with hypertensive urgencies are required to assess the final value of i.v. drugs in these patients. However, our data demonstrate that the frequently observed use of i.v. drugs in emergency departments is not harmful for patients with hypertensive urgencies. What this study adds K Our data demonstrate a similar efficacy of oral captopril and i.v. urapidil in patients with hypertensive urgencies. K No severe side effects have been observed after the application of i.v. urapidil. K Our data provide some evidence that i.v. drugs are not harmful in the treatment of hypertensive urgencies.
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